MiR‐30e‐induced apoptosis and benefited imatinib treatment in chronic myeloid leukaemia via inhibition of BCR‐ABL 25 and repressed proliferation of hepatocellular carcinoma cells via targeting P4HA1 26. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.